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There are two general approaches to transplantation of the liver. With 
the first, the diseased native liver is removed and replaced with a homograft 
(orthotopic transplantation). The alternative technique is the insertion of 
an extra liver at an ectopic site (auxiliary homotransplantation). The latter 
procedure has had only sporadic and for the most part unsuccessful trials. In 
contrast, more than 500 orthotopic transplantations have been carried out 
throughout the world, and with increasing numbers of successes, particularly 
in recent years. 
The experimental work justifying clinical trials of liver transplantation 
was performed about two decades ago and has been thoroughly summarized in a 
number of reviews (1, 2). In this chapter we will discuss only human trans-
plantation and with the main emphasis on the orthotopic procedure. 
INDICATIONS FOR LIVER TRANSPLANTATION 
Between our own experience (2) and that of the English team working at 
Cambridge and King's College Hospital in London (3), about 400 liver trans-
plantations had been performed by the summer of 1982. At least one hundred 
additional cases had been compiled in a dozen or more other centers (2). Most 
of the publications describing this experience have not placed much emphasis 
on the criteria for candidacy, and for this reason the following assessment is 
based largely on our own experience with 237 consecutive recipients treated 
from 1 March 1963 through April 1982. One hundred and twelve were classified 
as pediatric recipients (Table 1), with ages ranging from 5 months to 18 
years. The 125 adults (Table 2) were 19 to 68 years old. 
Experience has taught us the importance of systematically reviewing the 
features shown in Table 3 for any potential liver recipients. An important 
consideration is the so called "propriety factor" which is judged in part by 
how much meaningful life is thought to be left to the patient without trans-
plantation. Other considerations include the possibility of recurrence in a 
- 3 - r 
transplant of the disease which destroyed the native liver, and by the pres-
ence of other factors such as prior abdominal operations and the state of 
metabolic deterioration that can jeopardize the prognosis. From our exper-
ience, a fairly complete understanding has evolved with many specific diseases 
about what advice to give prospective recipients and their families, when and 
if the operation should be decided upon, how much risk there is of deteriora-
tion and death during the search for a donor organ, and what are the technical 
difficulties to be anticipated during the transplantation (Table 3). 
At present, candidacy is restricted to patients who are less than 55 
years old, who are free of extrahepatic infection, and who do not have an 
extrahepatic malignancy. Our general guideline has been that transplantation 
for non-neoplastic liver disease becomes justifiable with the advent of social 
and vocational invalidism (4). This condition usually is reflected in re-
peated hospitalizations for encephalopathy, variceal hemorrhage, hepato-renal 
syndrome, uncontrolled coagulation disorders, intractible ascites, and other 
complications of hepatic disease. 
PRINCIPLES OF EVALUATION 
The workup includes confirmation of the prior diagnosis, analysis of 
residual liver function, measurement of the recipients' intellectual and 
psychiatric state, assessment of abnormalities of extrahepatic organ systems, 
and determination, insofar as possible, if liver replacement will be anatomic-
ally possible. The last detail has been particularly important. In about 10% 
of the recipients treated early in our experience portal vein thrombosis or 
congenital anomalies were found at operation, making ,the usual procedure of 
orthotopic transplantation impossible. All of these recipients died. In 
recent years the systematic use of ultrasonography and computerized axial 
tomography (CAT) has made tentative identification possible of many such 
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situations. If there are questions about the portal vein after the non-inva-
sive diagnostic studies, angiography should be performed. 
For each of the diseases which may lead to hepatic transplantation, it is 
important for the health care team to know if recurrence of the original 
disease can be expected in the homograft. This factor can be a relative, 
although not an absolute, contraindication to liver transplantation with at 
least 2 diagnoses. Patients whose indication for transplantation is a primary 
hepatic IlBlignancy have had an exceptionally high incidence of tumor recur-
rence. Thus, candidates for total hepatectomy and transplantation for the 
indication of hepatic malignancy must be screened with exceptional care. It 
is probable that certain kinds of hepatic neoplasms including fibrolamellar 
hepatomas, ma.lignancies complicating other hepatic disorders such as tyro-
senimia, alpha-1-antitrypsin deficiency and chronic aggressive hepatitis may 
be bona fide candidates in the future. 
Except for patients with hepatic cancer, the most serious problems with 
disease recurrence have been in patients with chronic active hepatitis caused 
by the B virus. The documentation of disease recurrence, leading to graft 
destruction and death has been unequivocal (2, 5). In the last six patients 
treated by us under these circumstances, five have developed recurrent dis-
ease, and in two the complication has already led to death. 
Recurrent disease also has been described or is a distinct possibility 
with primary biliary cirrhosis, Budd-Cniari syndrome, and sclerosing cholangi-
tis (2). However, there is now enough experience to permit the tentative 
conclusion that recurrence will not be common in these diseases. 
Patients with inborn errors of metabolism have provided an interesting 
opportunity for "metabolic engineering" (Table 1). When these disorders have 
been liver based, the metabolic specificity of the liver has remained perman-
ently that of the donor. Thus patients with alpha-1-antitrypsin disease, PiZZ 
- 5 
phenotype, have permanently assumed the Pi (protease inhibitor) type of the 
donor at the same time as the alpha-1-anti trypsin levels have increased to 
normal in the blood (6). The longest follow up of a patient with an inborn 
error has been more than twel ve years after liver replacement for Wi 1 son ' s 
disease. 
In assessing the feasibility of liver transplantation, the presence or 
absence of previous surgical operations is an important factor. Patients who 
have had portacaval shunts, or prior attempts at biliary tract reconstruction 
may present such severe technical problems as to preclude liver replacement. 
In spite of the handicap imposed by prior surgery, attempts are still being 
made to treat this kind of patient, but the perioperati ve mortality is in-
creased (2). 
TISSUE TYPING 
Tissue matching at the A B and D loci for selection of cadaveric kidney 
donors has had an extensive evaluation with disappointing results. Such 
efforts have been feasible in a population of uremic patients since the al-
ternati ve therapies of hemodialysis or peritoneal dialysis are available. 
Prospecti ve recipients of livers for whom the prospect of artificial organ 
support does not exist do not have this luxury and immunologic screening in 
attempts to find compatible donors is a luxury that almost never can be af-
forded. In many patients it has even been necessary to transplant livers to 
recipients who present the kinds of cytotoxins which cause hyperacute rejec-
tion of renal grafts. Fortunately the liver has been inexplicably resistant 
to this kind of humoral rejection and the results have not been substantially 
different than in patients with negative cross matches (2, 4). It has even 
been possible in the event of dire emergencies to violate the ABO blood group 
guidelines that were designed to avoid subjecting an organ to preformed anti-
graft isoagglutinins (4). 
r 
THE DONOR OPERATION 
It my be that the most important factor in obtaining a satisfactory 
liver for transplantation is the wise screening of donors with the elimination 
of those whose physiologic situation could jeopardize vital organ function in 
advance of the procurement operation. Hepatic function tests of the donor are 
important, but in addition it may be dangerous for the recipient to procede 
with donor hepatectomy in the face of cardiovascular instability, a need for 
excessive vasopressor support, or an excessive period (several days) between 
injury and pronouncement of brain death. If renal function of the donor 
deteriorates, this suggests poor perfusion of other organs. The details of 
liver harvest have been well standardized (1, 7), and consist of skeletonizing 
the structures entering and leaving the liver. 
The donor operation is best done through a midline sternotomy and celiot-
omy extending from the sternal notch to the pubic symphysis. It is important 
to assess the possibility of anomalies of the hepatic arterial supply (Figure 
1) • Some of the anomalies are not serious. For example an artery to the left 
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lateral segment commonly arises from the left gastric artery, but the vessel 
can be preserved in continuity with its left gastric origin and coeliac axis 
allowing a single anatomosis in the recipient. If part of the blood supply of 
the liver comes from the superior mesenteric artery, the anomalous vessel 
almost always lies directly posterior to the portal vein (Figure 1) and can be 
easily identified there with a finger placed through the foramen of Winslow. 
If the hepatic blood supply is derived from both the superior mesenteric 
artery and coeliac axis, the two vessels of origin can be joined into a common 
trunk permitting a single anastomosis to the hepatic artery (Figure 2) or 
alternati vely an aortic segment can be removed in continuity with both the 
superior mesenteric artery and coeliac axis and anastomosed to the recipient 
aorta. 
- 7 -
Once the skeletonization has been carried out the final steps are planned 
which usually take into account the protection of other organs such as the 
kidneys or even the heart. The donor is anti-coagulated with heparin, and 
large cannulas are inserted into the distal aorta and terminal inferior vena 
cava to allow in situ infusion of cold solution and bleeding off of central 
blood volume, respectively (Figure 3). 
The portal vein perfusion with cold lactated Ringer's solution is begun 
while there is still an effective donor circulation. This has the effect of 
reducing the temperature of the liver tissue while an adquate flow of oxygen-
ated arterial blood is still present. It also adds protection to the kidney 
and other organs since donor core temperatures during the pre-cooling phase 
drift quickly down to 320C at the same time as the liver temperature drops 
several degrees below this. When the pre-cooling is terminated, in situ 
aortic flushing of the liver, kidneys or other organs can be done (Figure 3). 
By following this sequence all of the abdominal organs are cooled and can 
be quickly removed. If heart donation is also desired, the heart is removed 
• 
at about this time. The early function of cadaveric kidneys obtained during 
heart and liver procurement (7) or both has been far better than that achieved 
in our center and elsewhere with renal procurement alone. This advantage for 
renal recipients is probably due to the more discriminating donor selection 
and the greater intensity of surgical technical care that are features of the 
multiple organ harvesting operation. 
The chilled liver is placed in a plastic bag that contains Collins solu-
tion. The bag is sealed and packed in ice in a picnic refrigerator. A liver 
so processed can support the life of a recipient after storage for 12 to 24 
hours, but in humans an effort is made to keep the cold preservation time to 
less than six or eight hours (2). Using a preservation solution the Cambridge 
workers described similar time limitations. 
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After the organs are out the distal aorta and vena cava, and the iliac 
veins, and the iliac arteries are removed and stored separately in balanced 
electrolyte solution. These vascular segments often have been needed for the 
subsequent performance of transplantation. 
THE RECIPIENT OPERATION 
Good exposure is usually provided with a bilateral subcostal incision 
with an upper midline extension through which the xiphoid process is excised 
(Figure 4). A thoracic extension is occasionally needed. The recipient 
operation is much the same as already described for the donor with skeleton-
ization of the structures entering and leaving the 1i vel". The usual first 
step is to find the hilum, encircle it, and to dissect the proper and common 
hepatic artery, the common duct, and the portal vein. The inferior vena cava 
above and below the liver are encircled. 
The performance of these seemingly straightforward tasks can lead to one 
of the most difficult operations in surgery since almost all prospective liver 
recipients have portal hypertension and the majority have serious clotting 
< 
abnormalities. Patient with alcoholic or non-alcoholic cirrhosis have presen-
ted the most serious technical problems because of the scarring and antomic 
distortion which is present above and below the liver and in the retrohepatic 
area. In such patients it may be impossible to enter the bare area without 
causing a lethal hemorrhage and should this be the case, variations of the 
straight forward operation must be considered (2). Once the diseased native 
liver has been removed, the revascularization of the new liver is a straight 
forward exercise in vascular surgery. The vena caval anastomoses are carried 
out first (Figure 5) taking care to wash out air and potassium entrapped in 
the organ. The portal blood flow is usually restored first, and the hepatic 
arterial anastomosis is ordinarily performed as a final step (Figure 6). 
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Many kinds of biliary tract reconstruction have been tried throughout the 
years, (Figure 7) but we now perform either duct to duct anastomis with a T-
tube or internal stent, or a choledochojejunostomy to a Roux limb. With the 
use of these straightforward biliary anastomoses, the frequent problems with 
biliary tract obstruction or biliary fistula encountered early in our exper-
ience have virtually disappeared. In cases in which there is inadequate 
length of the homograft common duct the procedure preferred by caIne et al (3) 
can be used whereby the homograft common duct is anastomosed to the homograft 
gallbladder and the latter structure is used for the distal anastomosis to 
recipient duct or bowel (Figure 7 c, d). 
During the time when the new liver is being sewn in, it is necessary to 
occlude the splanchnic and systemic venous beds normally drained through the 
portal vein and inferior vena cava. These occlusions can usually be reason-
ably well tolerated during a 45 to 90 minute anhepatic phase in spite of major 
declines in cardiac output and variable hypotension. The relative safety of 
the occlusions depends upon the collaterals that develop with human liver 
disease. 
However some patients can be gravely jeopardized by the venous cross-
clamping and even in those who survive the cross-clamping, the practice may 
not be completely safe. Usually there is gross swelling of the intestine 
during the period of portal occlusion and subsequently many such patients 
suffer from third space fluid sequestration and postoperative renal failure. 
The extent to which these complex physiologic events have contributed to the 
high perioperative mortality of liver transplantation has not yet been delin-
eated. 
For this reason we have returned in all recent adult patients to the 
practice of veno-venous bypass which we abandoned long ago. Cannulas are 
introduced into the inferior vena cava through an iliac or femoral vein and 
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into the portal system through the open end of the transected portal vein. 
During the anhepatic phase the blood is returned to a reservoir and pumped to 
one of the large veins in the neck or arm. Wi th the use of the atraumatic 
pumps and heparin coated tubing which are now available, it has been possible 
to use the veno-venous bypasses without giving systemic heparin. The mainten-
ance of patient physiology has been strikingly improved during liver trans-
plantation with this technique and we now believe that it will become a stan-
dard part of the operation. 
IMMUNOSUPPRESSION 
All of the methods to prevent or reverse rejection of whole organs have 
been developed with the simpler procedure of renal transplantation. These are 
summarized in Table 4, exclusive of the earlier trials with total body irradi-
ation (12) which were never used for liver transplantation. Most liver recip-
ients treated by us until early 1980 were given "triple drug therapy" with 
azathioprine (or cyclophosphamide), prednisone and antilymphocyte globulin 
(ALG) (Table 4). Most of CaIne's experience from 1968 to 1980 was wi th the 
double drug therapy of azathioprine and prednisone (3). Neither 'the double or 
triple drug imrnunosuppressi ve regimens provided the rrargin of safety which 
might have made liver transplantation a practical undertaking in the 1960's 
and 1970's. There were problems with the control of rejection on one hand, 
and on the other with infectious complications that resulted from the high 
doses of drugs required to prevent or reverse rejection. 
In early 1980 a systematic trial was begun with the new double drug 
immunosuppressive program of cyclosporine and prednisone. This combination of 
agents was first worked out in cadaveric renal graft recipients (24, 25) and 
extrapolated almost unchanged to the care of hepatic recipients (2). Cyclo-
sporine is started a few hours preoperatively with an oral dose of 11.5 mglKg 
or with an intravenous dose of about one third this quantity. Cyclosporine is 
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continued daily, usually intravenously until diet is resumed and orally there-
after. The oral doses are reduced subsequently if nephrotoxicity develops. 
Steroids are also started on the day of operation, using a 5 day burst of 
prednisolone or solumedrol, and ending with a maintenance dose for adults of 
20 mg/per day after 5 days. Further reductions in cyclosporine and steroid 
doses are made on an individualized basis in the ensuing months. Initial 
mainentance therapy with steroids is scaled down in infants and children. 
REJECTION UNDER IMMUNOSUPPRESSION 
It is only a slight over simplification to say that there are two clini-
cal patterns of rejection which have much in coIIlDOn with acute and chronic 
hepatitis. With acute rejection the patient becomes abruptly jaundiced at the 
same time that there are variable increases in the transaminases indicating 
hepatic necrosis. If the steroid doses are increased, it is usually possible 
to reverse this kind of rejection, particularly if the base therapy is being 
provided by cyc10sporine. The timing of rejection is usually a week to 10 
days after transplantation, but acute rejection has been observed months or 
even years postoperatively, especially if the patient has beeri guilty of 
noncompliance. The histopathologic criteria of acute rejection were carefully 
worked out by Professor K. A. Porter of st. Mary's Hospital and Medical 
School, London, many years ago and consist of mononuclear cell invasion, 
secondary reticulum collapse of the lobular patterns, and less frequently the 
involvement of the arterial supply by humoral antibodies that has been des-
cribed in renal homografts. 
Chronic rejection under immunosuppression is characterized by slowly 
developing jaundice, deterioration of hepatic synthetic functions and minimal 
disturbances of tests that connote hepatic necrosis. Histopathologically 
chronically rejected livers may have arterial occlusive disease, fibrosis 
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which can progress to frank cirrhosis and the disappearance of hepatic ducts 
and ductules. 
SURVIVAL AITER LIVER REPLACEMENT 
The introduction of cyclosporine-steroid therapy has had a major influ-
ence upon the results after orthotopic liver transplantation. 
Before Cyclosporine (1963-1979) 
During this time, from 1963-1979, 170 patients underwent orthotopic liver 
transplantation under the conventional double drug or triple drug therapy 
summarized in Table 4. The one year survival ranged between 28.8 and 50% 
throughout this time, but without an identifiable trend of improvement. The 
results during this 16 year period are summarized in Figure 8. 
Of the 170 patients entered into this series, 56 lived out the first 
postoperative year. Twenty-three subsequently died (2). Although 13 of the 
23 late deaths were in the second postoperative year losses occurred as late 
as 6 years. Of the original 170 patients, 33 (19.4%) are still alive after 
followups of 4 to 13 1/3 years. Between 1963 and 1979, there was an almost 
equal division between adult and pediatric recipients. From the sixth month 
onward the younger patients had about a 10% survival advantage. 
The siren call of occasional spectacular successes interspersed with a 
larger number of failures was also heard in the Cambridge-King's College 
trials from the beginning of that program in 1968 through early 1980 (3). In 
the English series, 22 (23.7%) of the first 93 recipients lived for at least 
one year (Figure 8), with 11 subsequent deaths during the second to sixth 
years; at the time of last reporting the 11 survivors had been followed for 1 
to 6 years. 
The Cyclosporine Era (1980-1982) 
The predictability and reliability with which liver transplantation could 
be carried out improved abruptly with the first trials of cyclosporine-steroid 
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therapy (2, 3), and this promise has been sustained with subsequent exper-
ience. Since 1980, the majority of liver recipients have been brought through 
the early postoperative convalescence and have been able to leave the hospital 
for out-patient care. By the first of May, 1982, 40 recipients had been 
treated with this new immunosuppression with the survival projections shown in 
Figure 8. Since then the survival of pediatric recipients has been maintained 
at about the same level, although less favorable results in adults have 
brought the 1 year survival curve down. In addition, 3 of the patients trea-
ted with cyclosporine and steroids who reached or passed the 1 year mark died 
in their 13th, 16th, and 20th postoperative months. The causes of the late 
deaths were recurrent carcinoma, recurrent Budd-Chiari syndrome, and chronic 
rejection (with unsuccessful retransplantation). 
The influence of cyclosporine upon survival in the Cambridge-King's 
College trials has not yet been clearly defined (3), in part because the drug 
has not been used regularly and in part because it has been started late in 
most cases after an initial course of azathioprine and steroid. Nevertheless, 
improv~d results have been attributed by caIne et al to the better immunosup-
pression which they can now provide (3). 
CAUSES OF MORTALITY 
In both the early trials of liver transplantation under conventional 
immunosuppression and those wi th cyclosporine-steroid therapy, the principal 
mortali ty after liver transplantation has been early. Detailed analyses of 
the causes for this mortality have been published (1, 2). Throughout the 
years, the causes for failure have included the use of grafts damaged by 
ischemia, massive operative hemorrhage, thrombosis of the reconstituted homo-
graft blood supply, intraoperative cerebral air embolism, Qnsuspected recip-
ient abnormalities (particularly of the portal triad structures), hopeless 
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anatomical situations created by multiple previous operations, irreversible 
pre-existing debilitation, and defective biliary tract reconstruction. 
In addition, acute or subacute homograft rejection was an undoubted 
factor, but one whose dimensions could not be clearly delineated. At autopsy, 
histopathologic findings of acute rejection have been found in the minority of 
cases. This prompted speculation in the earlier days when biopsy was not 
often performed that over immunosuppression, especially with prednisone, may 
have been responsible for unnecessary deaths. However when serial biopsies 
were obtained in later cases (2) this simplistic view had to be revised. Many 
of the biopsies contained unmistakable findings of rejection for which the 
appropriate response had been more steroids. Yet after death, which was most 
commonly caused by terminal infection, findings of rejection were absent. 
This same chain of deadly events is still seen up to the present time, but 
less frequently than before. Under such circumstances, it may be difficult to 
find a single explanation for failure. 
In contrast, assessment of the reasons for late deaths has been less 
ambiguous. Recurrent liver failure was responsible for the deaths of 3/4 of 
the 26 patients who died after 1 year if the 5 who died after attempted re-
transplantation are included (2). The dominant pathological diagnoses in late 
failing grafts have been chronic rejection in the majority of cases, with 
biliary obstruction, recurrent carcinoma, chronic hepatitis, portal vein 
thrombosis, and recurrent Budd-Chiari syndrome being progressively more dis-
tant contenders (2). 
These findings in chronically surviving patients were remarkedly differ-
ent from those reported by Calne et al (3) in 11 patients who died after 1 
year. Recurrent carcinoma was the min homograft abnormality in 5 of their 
patients. In the other 6 grafts, there was biliary sludge and cholangitis. 
Chronic rejection was not mentioned. Thus, our findings have suggested that 
ongoing problems with immunologic control will continue to take a gradual toll 
long after transplantation, whereas the interpretation of the pathologic 
findings in the English recipients have minimized the importance of chronic 
rejection. 
STEPS TO REDUCE MJRTALITY 
A glance at the life survival curves from the earlier days of our exper-
ience, or even in recent times (Figure 8) shows that the highest pri?rity for 
improved management is reduction of the perioperative mortality. However the 
fact that the survival curves continue to decline even after 3 or 4 months 
means that strategies to circumvent late mortality will also be important. 
The way in which the original disease dictates the technical difficulty 
of transplantation (see Table 3) waS not clearly perceived until relatively 
recently. The consequent hidden risk factor could be improved by trying to 
treat patients with "dangerous" diseases like postnecrotic cirrhosis, alcoho-
lic cirrhosis, and secondary biliary cirrhosis at an earlier time. When such 
patients have had previous operations at or near the hepatic hilum, liver 
transplantation may not be a reasonable option especially if the patient's 
physical and metabolic decay is extreme. 
Veno-venous bypasses during removal of the recipient liver and implanta-
tion of the new organ were discussed in an earlier section. Toe use of by-
passes may be mandatory in patients who have undergone a previous portacaval 
shunt, since the venous collaterals which usually make it safe to occlude the 
inferior vena cava and portal vein are apt to have undergone involution. As 
noted earlier, other patients are probably candidates for veno-venous bypasses 
as well, and we are now doing bypasses on all adults. 
For B-virus carriers who have postnecrotic cirrhosis and for patients 
with hepatic malignancies, there is not yet enough evidence to foreclose liver 
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transplantation as an avenue of treatment. However, it will be important for 
workers in the field to pool data in order to arrive at a concensus. Too many 
late deaths from recurrence of these disease have occurred, a problem that has 
not been so overwhelming with any of the other disorders that have recurrence 
potential. 
It has become uncommon to have defective vascular or biliary tract anas-
tomoses. The single most common problem has become the marginally functioning 
donor li vel' • When this has occurred, it usually has been found that the 
orderly stages of donor liver removal including the "pre-cooling" step with an 
intact hepatic artery have been abridged or otherwise changed from the stan-
dard procedure. The second most common explanation has been acceptance of a 
physiologically unstable donor who frequently has required large amounts of 
vasopressor medications for maintenance of blood pressure. Abandonment of the 
donor effort under the questionable circumstances will be increasingly neces-
sary. 
When a transplanted liver fails either early or late from rejection or 
other causes, aggressive attempts at retransplantation usually offer the only 
chance for survival. One of the commonest judgement errors we have made is to 
hope vainly for improvement in hepatic function until the hope of reinterven-
tion was lost. Despite this, more than 30 patients have undergone retranspla-
ntation since 1968 (2). Only recently have these efforts been encouraging. 
More than a dozen patients treated in 1980-1982 had retransplantation a few 
days to 20 months after primary grafting and the majority are surviving with 
subsequent followups of up to ~/OyearsK 
The performance of retransplantation has usually been surprisingly 
easy. The procedure has been greatly simplified by retaining cuffs from the 
suprahepatic and infrahepatic vena cava and from the portal vein of the first 
graft. Usually it has been necessary to perform the arterial anastomosis 
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proximal to the previous site of anastomosis. Failure to do this in a recent 
base resulted in thrombosis of the arterial segment retained from the failed 
first graft for anastomosis to the celiac axis of the second liver. 
THE OPTION OF AUXILIARY LIVER TRANSPLANTATION 
Clinical efforts to transplant an extra liver (auxiliary transplantation) 
wi thout removal of the diseased native organ have been discouraging as has 
been noted by Fortner et al (26). Of more than 50 well documented auxiliary 
transplantations only two could be pronounced an unequivocal success, one in 
New York City (26) and the other in Paris (27). 
Auxiliary liver transplantation may be useful in patients with potential-
ly reversible hepatic disease. The extra liver could be used as a temporary 
support organ and later removed. In addition, we have seen increasing numbers 
of patients with chronic disease whose portal vein has clotted in the hepatic 
hilum making it technically impossible to consider liver replacement. Auxil-
iary liver transplantation might be an option under such circumstances or in 
, 
patients \oJi th extensive previous surgery in the right upper quadrant for whom 
orthotopic transplantation would be excessively difficult or impossible. The 
physiologic requirements for auxiliary liver transplantation have been dis-
cussed elsewhere (28, 29). 
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Figure 1. Anomalies of hepatic arterial blood supply. From ph~wI et aI, 7. 
Figure 2. The management of a common graft anomaly in which part of the liver 
blood supply is derived from the superior mesenteric artery. Note that 
the celiac axis is anastomosed to one end of the main superior mesenteric 
artery and the other end is used for anastomosis to a recipient vessel. 
From Shaw et al, 8. 
Figure 3. En bloc infusion of liver and kidneys. Note the infusion cannulas 
in the aorta and splenic veins, and the bleed-off cannula in the inferior 
vena cava. From Shaw et aI, 7. 
Figure 4. Incisions for orthotopic liver transplantations. Note that several 
extensions may be made from the basic right subcostal inciSion, A to A, 
that is almost always used. More than one of the depicted extensions may 
be required in a given patient. From Starzl et aI, 9. 
Figure 5. Initial steps in the implantation of a new liver. (A), Infusion 
with lactated Ringer's solution in order to wash out the potassium rich 
Collins solution. (B), Completion of suprahepatic anastomosis. (C), 
Completion of infrahepatic vena cava anastomosis. Note in B and C the 
escape of air bubbles which if not expelled could lead to air embolism. 
From Starzl et aI, 10. 
Figure 6. Completion of vascular reconstructions at hilum, and duct to duct 
biliary anastomosis over aT-tube stent. From Starzl et aI, 11. 
Figure 7. Methods of biliary tract reconstruction that have been used with 
--- .. _---------
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liver transplantation. The techniques shown in E and F are so defective 
that they have been abandoned. Depending upon the anatomic and clinical 
circumstances, each of the other methods may be useful in individual 
cases (see text for discussion). 
Figure 8. The actuarial survival of patients treated with cyclosporine and 
low dose steroids compared to the actual one-year survival obtained under 
conventional llDrnunosuppression by us (azathioprine) and by the workers at 
Cambridge. The data for the Cambridge curve was obtained from published 
reports (3). From Starzl et al, 2. 
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